NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study

Functional Mitral Regurgitation Clinical Trial

Official title:

NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03929913
• Other study ID #: 190088
• Secondary ID: 19-H-0088
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 7, 2019
• Est. completion date: December 31, 2025

Study information

• Verified date: July 2023
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research protocol tests a new technique and devices that we have developed to treat functional mitral valve regurgitation, called transcatheter mitral valve cerclage annuloplasty, otherwise known as "cerclage". Functional mitral valve regurgitation is a condition caused by damaged heart muscle involving the left ventricle which results in mitral valve leakage. This leakage causes heart failure (breathlessness and lack of energy especially when walking or exercising, and hospital admissions for fluid buildup). This is an early feasibility study (EFS) evaluation of special devices, permanently implanted in the heart, to perform mitral cerclage annuloplasty. Mitral cerclage annuloplasty is a catheter procedure performed under X-ray and ultrasound guidance without surgery. The cerclage devices compress the mitral valve like a purse-string. The cerclage device has a special feature that prevents a coronary artery from getting squeezed as part of this purse-string. The protocol has been changed to allow patients who have mitral valve regurgitation despite prior Mitra-Clip treatment, and to allow patients who have symptomatic heart failure with mild mitral regurgitation.

Description:

Functional mitral regurgitation (also known as secondary mitral regurgitation) is a common complication of left ventricular dysfunction. Ventricular dysfunction leads to dilation, which in turn leads to mitral annular dilation and leaflet traction. This causes a failure of coaptation of the otherwise intact leaflets of the mitral valve, leading to regurgitation through a central orifice between the mal-coapting leaflet tips. Functional mitral regurgitation contributes to heart failure symptoms. Transcatheter Mitral Cerclage Annuloplasty (TMCA) is a new catheter technique that reduces the septal-lateral dimension of the dilated annulus through circumferential compression, prevents extrinsic compression and entrapment of coronary arteries by incorporating a protection element, and exhibits planar discordance that achieves annular reduction even when the coronary sinus is anatomically located along the posterior left atrial wall. This is an entirely right-sided procedure and device.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 19
• Est. completion date: December 31, 2025
• Est. primary completion date: February 23, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 99 Years

Eligibility

• INCLUSION CRITERIA:

1. Adults age >=21 years

2. Symptomatic functional mitral valve regurgitation

1. Mild or greater mitral valve regurgitation, LVEF <= 0.50, and NYHA class III

• IV heart failure

2. Moderate or greater mitral valve regurgitation and NYHA II - IV heart failure, irrespective of LV systolic function

3. On optimal medical therapy for at least one month

4. Left ventricular ejection fraction >=0.20 assessed by echocardiography, CT, or CMR

5. Suitable coronary venous anatomy for Transcatheter Mitral Cerclage Annuloplasty based on pre-procedural cardiac CT or coronary venogram

6. Concordance of the Study Eligibility Committee

7. If present, a MitraClip was implanted at least 30 days previously

EXCLUSION CRITERIA:

1. Subjects unable to consent to participate

2. Subjects unwilling to participate or unwilling to return for study follow-up activities.

3. Prior cardiac implanted electronic devices (CIED) likely to be entrapped by cerclage. -- Candidates with coronary sinus or left ventricular pacing or defibrillation leads that are not likely to be entrapped by cerclage, evident on baseline CT or angiogram, are eligible to participate.

4. TAVR within 6 weeks

5. Intended concurrent structural heart procedure, such as aortic or tricuspid valve intervention

6. Aortic stenosis more than mild in severity

7. Single-leaflet MitraClip detachment, if present

8. Pregnancy or intent to become pregnant prior to completion of all protocol follow-up procedures

Related Conditions & MeSH terms

• Functional Mitral Regurgitation
• Mitral Valve Insufficiency

Intervention

Device:
• Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA)
The Transcatheter Mitral Cerclage Annuloplasty implant has two components, with or without a coronary artery protection element, and the wishbone lock with coronary sinus and right ventricular outflow track limbs. Procedure is performed from a trans-jugular venous approach. Coronary guidewires and microcatheters are used to navigate into a coronary vein to the target capture catheter. The implant is then attached to the back end of the guidewire and pulled out of the internal jugular sheath. The position of the implant is adjusted so the coronary protection element lies directly over any underlying branch of the left coronary artery. The wishbone lock is advanced over the two limbs of the implant and the desired tension is titrated to the degree of mitral regurgitation. Coronary angiography is performed to confirm there is no coronary compression. After desired tension has been achieved, the wishbone lock is locked and the two limbs of the implant are cut with a cutter catheter.

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	Carilion Medical Center	Roanoke	Virginia
United States	MedStar Washington Hospital Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Primary Endpoint is Technical Success	The primary endpoint is Technical success. This endpoint is measured at exit from the catheterization laboratory. All of the following must be present: Alive; Successful deployment and correct positioning of a single intended Transcatheter Mitral Cerclage Annuloplasty (TMCA). Repositioning and recapture of the device, if needed, is not classified as failure.; Retrieval of the TMCA delivery system; Absence of TMCA-related coronary artery compression and absence of additional procedure such as percutaneous coronary intervention (PCI) to relieve coronary artery compression.; No additional unplanned or emergency surgery or re-intervention related to the TMCA or delivery system.	1 minute following procedure discharge (Exit from the catheterization laboratory)
Secondary	The Secondary Endpoint is Procedural Success	The secondary endpoint is Procedural success This endpoint is measured at 30 days. All of the following must be present: Technical success; No Transcatheter Mitral Cerclage Annuloplasty (TMCA) device-related Serious Adverse Events, defined as VARC-2 life-threatening bleeding, major vascular or cardiac complications related to the TMCA requiring unplanned reintervention or surgery.	Day 30 post procedure

External Links

•   NIH Clinical Center Detailed Web Page